VolitionRx (NYSE:VNRX) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of VolitionRx (NYSE:VNRX) in a research note published on Sunday morning. The firm issued a sell rating on the stock.

Several other equities analysts also recently weighed in on VNRX. Benchmark restated a hold rating on shares of VolitionRx in a research report on Friday, August 16th. Cantor Fitzgerald restated an overweight rating and set a $2.50 target price on shares of VolitionRx in a report on Thursday, May 16th.

VolitionRx Stock Performance

VolitionRx stock opened at $0.72 on Friday. The company’s fifty day moving average price is $0.64 and its 200 day moving average price is $0.75. The stock has a market capitalization of $59.71 million, a P/E ratio of -1.57 and a beta of 1.13. VolitionRx has a 1 year low of $0.43 and a 1 year high of $1.38.

VolitionRx (NYSE:VNRX) last released its earnings results on Wednesday, August 14th. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01. The company had revenue of $0.40 million for the quarter, compared to analysts’ expectations of $0.34 million. Sell-side analysts predict that VolitionRx will post -0.31 EPS for the current year.

Insider Buying and Selling

In other news, Director Guy Archibald Innes bought 150,000 shares of the firm’s stock in a transaction on Tuesday, August 20th. The shares were bought at an average cost of $0.67 per share, for a total transaction of $100,500.00. Following the acquisition, the director now directly owns 406,683 shares of the company’s stock, valued at approximately $272,477.61. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 12.80% of the stock is owned by company insiders.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.